亨廷顿病的治疗和研究中的差异
Ashley Madera1, Clare Schrodt, Adys Mendizabal
1Department of Neurology, David Geffen School of Medicine at the University of California, Los Angeles (UCLA), Los Angeles, California, USA.
Current opinion in neurology
|May 21, 2025
概括
亨廷顿病的差异 亨廷顿病的差异
科学领域:
- 神经学和罕见疾病.
- 流行病学和健康差异
背景情况:
- 虽然已知常见神经系统疾病的差异,但对罕见疾病 (如亨廷顿病) 的不平等情况的了解较少.
- 了解这些差异对于公平的HD护理和研究至关重要.
研究的目的:
- 审查全球和美国的亨廷顿病流行病学.
- 突出HD诊断和各种患者群体的结果之间的差异.
- 讨论HD研究中有限的多样性对临床试验和治疗可访问性的影响.
主要方法:
- 对有关亨廷顿病流行病学的现有文献进行系统审查.
- 分析研究数据,包括ENROLL-HD纵向研究,重点关注人口和社会经济因素.
- 检查研究数据集以代表多样化的人口.
主要成果:
- 全球亨廷顿病的流行和发病率各不相同,拉丁美洲地区的病例数量较高.
- 北美黑人和拉丁裔患者的诊断和结果存在显著差异.
- 社会经济地位,教育程度和性别与HD诊断,获得护理和结果的差异有关.
- 在像ENROLL-HD这样的关键研究数据集中,占主导地位的白人非西班牙裔人口 (90%) 限制了在不同群体中对HD的理解.
结论:
- 种族,性别和社会经济差异在亨廷顿病的治疗和研究中很明显.
- 解决这些不平等问题对于改善所有HD患者获得护理,参与临床试验和治疗结果至关重要.
- 增加HD研究的多样性对于验证临床试验结果和确保全球获得新疗法至关重要.
相关概念视频
01:15Parkinson's Disease: Overview
405
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
405
01:12Hazard Ratio
72
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
72
01:29Documentation in Long-Term and Home Healthcare Setting
864
Documentation in long-term care facilities and home healthcare settings is crucial for ensuring continuous, coordinated, and comprehensive care for patients. Each setting has its specific documentation processes and tools:
Long-Term Care Facilities
Long-Term Care Facilities
864
01:22Lysosomal Hydrolases
3.7K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.7K
01:11Genome-wide Association Studies-GWAS
12.3K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
12.3K
01:15Methods of Documentation VI: Case Management Model
556
The case management model is a multidisciplinary approach that involves healthcare professionals from diverse disciplines, such as physicians, nurses, therapists, social workers, and pharmacists, working collaboratively to address the various needs of patients. Each healthcare professional brings unique expertise and perspectives, contributing to a more comprehensive understanding of the patient's condition and tailoring treatment plans accordingly.
For example, a patient with a chronic...
For example, a patient with a chronic...
556